Abstract
Cost-Effectiveness of Adjuvant Therapy for Stage IIIA Melanoma Is Poor Even When Patients Are Risk-Stratified by Gene Expression Profile
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have